STRO 001
Alternative Names: BN-301; STRO-001Latest Information Update: 29 Apr 2024
At a glance
- Originator Sutro Biopharma
- Developer BioNova Pharmaceuticals; Sutro Biopharma
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids
- Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Acute myeloid leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Leukaemia; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 31 Mar 2024 BioNova terminates both the BioNova Option Agreement and clinical development of STRO 001 in Greater China
- 31 Mar 2024 Suspended - Phase-I for Acute myeloid leukaemia in China (IV)
- 31 Mar 2024 Suspended - Phase-I for Diffuse large B cell lymphoma (Late-stage disease, Second-line therapy or greater) in USA (IV)